Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)

NCT04195139 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT04195139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04195139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)
Lead sponsor
University of Sydney
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 22, 2018
Completion date
December 31, 2025
Enrollment
103 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme